210 related articles for article (PubMed ID: 30747736)
21. Imaging of renal cell carcinoma in patients with acquired cystic disease of the kidney: comparison
Kitajima K; Yamamoto S; Kawanaka Y; Katsuura T; Fujita M; Nakanishi Y; Yamada Y; Hashimoto T; Suzuki T; Go S; Kanematsu A; Nojima M; Yamakado K
Jpn J Radiol; 2019 Feb; 37(2):165-177. PubMed ID: 30377936
[TBL] [Abstract][Full Text] [Related]
22. Uptake of cis-4-[18F]fluoro-L-proline in urologic tumors.
Langen KJ; Börner AR; Müller-Mattheis V; Hamacher K; Herzog H; Ackermann R; Coenen HH
J Nucl Med; 2001 May; 42(5):752-4. PubMed ID: 11337571
[TBL] [Abstract][Full Text] [Related]
23. Detection of 18F-FDG PET/CT Occult Lesions With 18F-DCFPyL PET/CT in a Patient With Metastatic Renal Cell Carcinoma.
Rowe SP; Gorin MA; Hammers HJ; Pomper MG; Allaf ME; Javadi MS
Clin Nucl Med; 2016 Jan; 41(1):83-5. PubMed ID: 26402128
[TBL] [Abstract][Full Text] [Related]
24. A prospective diagnostic accuracy study of F-18 fluorodeoxyglucose-positron emission tomography/computed tomography in the evaluation of indeterminate renal masses.
Ozülker T; Ozülker F; Ozbek E; Ozpaçaci T
Nucl Med Commun; 2011 Apr; 32(4):265-72. PubMed ID: 21301376
[TBL] [Abstract][Full Text] [Related]
25. F-18 FDG PET in detecting renal cell carcinoma.
Ak I; Can C
Acta Radiol; 2005 Dec; 46(8):895-9. PubMed ID: 16392617
[TBL] [Abstract][Full Text] [Related]
26. Diagnostic value of F-18 FDG PET/CT for local and distant disease relapse surveillance in surgically treated RCC patients: Can it aid in establishing consensus follow up strategy?
Elahmadawy MA; Elazab MSS; Ahmed S; Salama M
Nucl Med Rev Cent East Eur; 2018; 21(2):85-91. PubMed ID: 30070347
[TBL] [Abstract][Full Text] [Related]
27. The acceleration of glucose accumulation in renal cell carcinoma assessed by FDG PET/CT demonstrated acquisition of resistance to tyrosine kinase inhibitor therapy.
Nakaigawa N; Kondo K; Ueno D; Namura K; Makiyama K; Kobayashi K; Shioi K; Ikeda I; Kishida T; Kaneta T; Minamimoto R; Tateishi U; Inoue T; Yao M
BMC Cancer; 2017 Jan; 17(1):39. PubMed ID: 28068944
[TBL] [Abstract][Full Text] [Related]
28. 18F-FDG PET/CT imaging for an early assessment of response to sunitinib in metastatic renal carcinoma: preliminary study.
Vercellino L; Bousquet G; Baillet G; Barré E; Mathieu O; Just PA; Desgrandchamps F; Misset JL; Hindié E; Moretti JL
Cancer Biother Radiopharm; 2009 Feb; 24(1):137-44. PubMed ID: 19243256
[TBL] [Abstract][Full Text] [Related]
29. A Review of Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) in Renal Cell Carcinoma (RCC).
Ahn T; Roberts MJ; Abduljabar A; Joshi A; Perera M; Rhee H; Wood S; Vela I
Mol Imaging Biol; 2019 Oct; 21(5):799-807. PubMed ID: 30617728
[TBL] [Abstract][Full Text] [Related]
30. PET/CT and choline: diagnosis and staging.
Farsad M; Schwarzenböck S; Krause BJ
Q J Nucl Med Mol Imaging; 2012 Aug; 56(4):343-53. PubMed ID: 23013664
[TBL] [Abstract][Full Text] [Related]
31. Clinical role of F-18 fluorodeoxyglucose positron emission tomography for detection and management of renal cell carcinoma.
Ramdave S; Thomas GW; Berlangieri SU; Bolton DM; Davis I; Danguy HT; Macgregor D; Scott AM
J Urol; 2001 Sep; 166(3):825-30. PubMed ID: 11490227
[TBL] [Abstract][Full Text] [Related]
32. Clinically significant association between the maximum standardized uptake value on 18F-FDG PET and expression of phosphorylated Akt and S6 kinase for prediction of the biological characteristics of renal cell cancer.
Mizuno T; Kamai T; Abe H; Sakamoto S; Kitajima K; Nishihara D; Yuki H; Kambara T; Betsunoh H; Yashi M; Fukabori Y; Kaji Y; Yoshida K
BMC Cancer; 2015; 15():1097. PubMed ID: 25784113
[TBL] [Abstract][Full Text] [Related]
33. Prostate cancer PET tracers: essentials for the urologist.
Fraum TJ; Ludwig DR; Kim EH; Schroeder P; Hope TA; Ippolito JE
Can J Urol; 2018 Aug; 25(4):9371-9383. PubMed ID: 30125515
[TBL] [Abstract][Full Text] [Related]
34. Prognostic Value of Pretreatment Metabolic Tumor Volume and Total Lesion Glycolysis Using 18F-FDG PET/CT in Patients With Metastatic Renal Cell Carcinoma Treated With Anti-Vascular Endothelial Growth Factor-Targeted Agents.
Hwang SH; Cho A; Yun M; Choi YD; Rha SY; Kang WJ
Clin Nucl Med; 2017 May; 42(5):e235-e241. PubMed ID: 28288043
[TBL] [Abstract][Full Text] [Related]
35. Diagnostic performance of 18F-FDG PET or PET/CT in restaging renal cell carcinoma: a systematic review and meta-analysis.
Ma H; Shen G; Liu B; Yang Y; Ren P; Kuang A
Nucl Med Commun; 2017 Feb; 38(2):156-163. PubMed ID: 27824726
[TBL] [Abstract][Full Text] [Related]
36. Clinical impact of (18)F-FDG PET in management of patients with renal cell carcinoma.
Rodríguez Martínez de Llano S; Jiménez-Vicioso A; Mahmood S; Carreras-Delgado JL
Rev Esp Med Nucl; 2010; 29(1):12-9. PubMed ID: 20022140
[TBL] [Abstract][Full Text] [Related]
37. Metastatic Renal Cell Cancer Treated With Antiangiogenic Therapy Monitoring by 18F-FDG PET/CT.
García Garzon JR; Bassa P; Llinares E; Soler M; Moragas M; Riera E
Clin Nucl Med; 2015 Nov; 40(11):910-1. PubMed ID: 26252325
[TBL] [Abstract][Full Text] [Related]
38. [Tracers in oncology - preclinical and clinical evaluation].
Krause BJ; Schwarzenböck S; Schwaiger M
Nuklearmedizin; 2010; 49 Suppl 1():S41-5. PubMed ID: 21152689
[TBL] [Abstract][Full Text] [Related]
39. 131 I-cG250 monoclonal antibody immunoscintigraphy versus [18 F]FDG-PET imaging in patients with metastatic renal cell carcinoma: a comparative study.
Brouwers AH; Dorr U; Lang O; Boerman OC; Oyen WJ; Steffens MG; Oosterwijk E; Mergenthaler HG; Bihl H; Corstens FH
Nucl Med Commun; 2002 Mar; 23(3):229-36. PubMed ID: 11891480
[TBL] [Abstract][Full Text] [Related]
40. Tyrosine-Kinase Inhibitors Therapies with Mainly Anti-Angiogenic Activity in Advanced Renal Cell Carcinoma: Value of PET/CT in Response Evaluation.
Ranieri G; Marech I; Niccoli Asabella A; Di Palo A; Porcelli M; Lavelli V; Rubini G; Ferrari C; Gadaleta CD
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28891933
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
